ERBB2 and breast carcinoma: It is thought that the ability of cyclin D1 to activate CDK4 is critical for driving tumorigenesis, and that CDK4-associated kinase activity is required to maintain this tumorigenesis, as shown in mice with Her2-induced, but not Wnt-1-induced [29] and Ras-induced breast cancer [30].